RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:MRNA) with a Outperform and raises the price target from $135 to $160.
RBC Capital Maintains Outperform on Moderna, Raises Price Target to $160
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.